TDC
COGT icon

Thompson Davis & Co’s Cogent Biosciences COGT Stock Holding History

Thompson Davis & Co’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-217
Closed -$12K – 721
2018
Q2 		$12K Buy
+217
New +$10.4K 0.03% 401

Other funds holding COGT

AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
CI
Cowen Inc New York $1.39B AUM 60.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Thompson Davis & Co's COGT Position: Q3 2018 in Review

Thompson Davis & Co sold out of Cogent Biosciences (COGT) in Q3 2018, closing a stake of 217 shares — an estimated $12K sold.

Thompson Davis & Co first reported a position in COGT in Q2 2018 and held it in 1 quarter. The position peaked at $12K in Q2 2018. 48 funds tracked by Wall St. Rank hold COGT as of Q3 2018.

  • Thompson Davis & Co reported no remaining Cogent Biosciences position as of Q3 2018 after selling out during the quarter.
  • Thompson Davis & Co sold 217 Cogent Biosciences shares in Q3 2018, an estimated $12K.
  • Thompson Davis & Co first reported a position in Cogent Biosciences in Q2 2018 and held it in 1 quarter.
  • Thompson Davis & Co's Cogent Biosciences position peaked at $12K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Cogent Biosciences as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.